What does Medtronic plc do?

Medtronic is the largest pure-play medical device maker on the planet. If a heart needs a pacemaker, a catheter valve (TAVR) or an ablation to fix an arrhythmia, the equipment is very likely theirs. Four businesses (fiscal 2026, $36.4 billion): Cardiovascular $13.98 billion (~38%), Neuroscience $10.3 billion (~28% — spine, neurostimulators, cranial navigation), Medical Surgical $8.9 billion (~24% — staplers, surgical energy, monitoring) and Diabetes $3.1 billion (~9% — MiniMed pumps). Two 2026 catalysts: (1) pulsed-field ablation (PFA) — the new way to fix atrial fibrillation without burning tissue — grew ~50% for the year with its PulseSelect and Affera catheters; (2) the Hugo surgical robot received FDA clearance (Dec 2025) and performed its first US commercial case at Cleveland Clinic (Feb 2026), challenging Intuitive Surgical's monopoly. The Diabetes unit is being separated: MiniMed went public (Nasdaq: MMED, March 2026) and the full split-off is expected by the end of 2026 — leaving a more focused, higher-margin Medtronic. Domiciled in Ireland (Galway); operations in Minneapolis; CEO Geoff Martha.

Why did Vectorial Data pick MDT?

Three reasons. (1) IT'S GROWING AGAIN: fiscal 2026 was its best revenue growth in a decade ($36.4 billion, +8.4%; +5.8% organic) and the latest quarter beat expectations (+9.9%); fiscal 2027 guidance calls for 6.75–7.25% organic and adjusted earnings of $5.90–6.00 (+7–8%). The stock rose ~7% on the report. (2) TWO PRODUCTS TAKING OFF: cardiac ablation grew ~50% for the year (and Medtronic is investing to expand Affera manufacturing on physician demand) and the Hugo robot is just starting its US commercial life — the robotic surgery market has been dominated by a single player for 20 years. (3) RELIABLE INCOME, CHEAP: 3.2% a year with 49 consecutive increases and ~$5.4 billion of free cash flow covering the payout; at $90.75 it trades at 14.1x expected earnings — well below the sector — with a Buy consensus from 25 analysts and a ~$98.84 target (+9%). The MiniMed separation (late 2026) leaves a more focused, higher-margin Medtronic.

What are the risks of investing in MDT?

#1: competition in its star product. In pulsed-field ablation, Boston Scientific (Farapulse) dominates — more than 500,000 patients treated and ~80% of the US market — and J&J and Abbott are pushing too; Medtronic's ~50% growth starts from a smaller base. Others: (2) Hugo vs Intuitive: the robot is only cleared for urology in the US and faces a rival with two decades of installed advantage; (3) tariffs: the company estimates a ~$250 million net hit in fiscal 2027; (4) earnings grow less than sales: in fiscal 2026 adjusted earnings rose just ~0.7% and the latest dividend increase was token-sized (~1.4%) — payout ~76%; (5) separation execution for MiniMed: it loses its fastest-growing unit (~13%); (6) it reports its fiscal 2027 first quarter on September 1 — results immediately ahead.

Does MDT pay dividends?

Yes. Medtronic plc pays a dividend of about 3.2% per year.

How can I buy MDT with little money?

You can buy fractional shares of MDT starting from a few dollars with any broker that offers fractional shares. The Vectorial Data method: invest the same amount in every pick, every time.

When was this MDT analysis last updated?

The MDT analysis was last updated on Invalid Date.

Stocks/MDT

MDT — Medtronic plc

HealthcareEuropeIrelandBlockchain certified

$90.75

Target: $98.84 (+8.9%)

P/E Ratio

24.3

P/E Forward

14.1

Dividend

3.2%

Market Cap

$115.8B

EPS

$3.73

Consensus

Buy

What they do

Medtronic is the largest pure-play medical device maker on the planet. If a heart needs a pacemaker, a catheter valve (TAVR) or an ablation to fix an arrhythmia, the equipment is very likely theirs. Four businesses (fiscal 2026, $36.4 billion): Cardiovascular $13.98 billion (~38%), Neuroscience $10.3 billion (~28% — spine, neurostimulators, cranial navigation), Medical Surgical $8.9 billion (~24% — staplers, surgical energy, monitoring) and Diabetes $3.1 billion (~9% — MiniMed pumps).

Two 2026 catalysts:

pulsed-field ablation (PFA) — the new way to fix atrial fibrillation without burning tissue — grew ~50% for the year with its PulseSelect and Affera catheters;
the Hugo surgical robot received FDA clearance (Dec 2025) and performed its first US commercial case at Cleveland Clinic (Feb 2026), challenging Intuitive Surgical's monopoly.

The Diabetes unit is being separated: MiniMed went public (Nasdaq: MMED, March 2026) and the full split-off is expected by the end of 2026 — leaving a more focused, higher-margin Medtronic. Domiciled in Ireland (Galway); operations in Minneapolis; CEO Geoff Martha.

Why we like it

Three reasons.

IT'S GROWING AGAIN: fiscal 2026 was its best revenue growth in a decade ($36.4 billion, +8.4%; +5.8% organic) and the latest quarter beat expectations (+9.9%); fiscal 2027 guidance calls for 6.75–7.25% organic and adjusted earnings of $5.90–6.00 (+7–8%). The stock rose ~7% on the report.
TWO PRODUCTS TAKING OFF: cardiac ablation grew ~50% for the year (and Medtronic is investing to expand Affera manufacturing on physician demand) and the Hugo robot is just starting its US commercial life — the robotic surgery market has been dominated by a single player for 20 years.
RELIABLE INCOME, CHEAP: 3.2% a year with 49 consecutive increases and ~$5.4 billion of free cash flow covering the payout; at $90.75 it trades at 14.1x expected earnings — well below the sector — with a Buy consensus from 25 analysts and a ~$98.84 target (+9%). The MiniMed separation (late 2026) leaves a more focused, higher-margin Medtronic.

Key Risk

#1: competition in its star product. In pulsed-field ablation, Boston Scientific (Farapulse) dominates — more than 500,000 patients treated and ~80% of the US market — and J&J and Abbott are pushing too; Medtronic's ~50% growth starts from a smaller base. Others:

Hugo vs Intuitive: the robot is only cleared for urology in the US and faces a rival with two decades of installed advantage;
tariffs: the company estimates a ~$250 million net hit in fiscal 2027;
earnings grow less than sales: in fiscal 2026 adjusted earnings rose just ~0.7% and the latest dividend increase was token-sized (~1.4%) — payout ~76%;
separation execution for MiniMed: it loses its fastest-growing unit (~13%);
it reports its fiscal 2027 first quarter on September 1 — results immediately ahead.

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked MDT on 2026-08-31 at $90.75.

Last updated: Invalid Date

Dividends received by the Vectorial portfolio

MDT has not paid a dividend to the portfolio yet.

Full Research

Qué hace. Medtronic plc (NYSE: MDT; domicilio Galway, Irlanda; operación Minneapolis; ~95,000 empleados; CEO Geoff Martha) es el mayor fabricante puro de dispositivos médicos del mundo. Segmentos (año fiscal 2026, cerrado el 24 de abril de 2026; ingresos $36,400 millones): Cardiovascular $13,980 millones (38%) — marcapasos, desfibriladores, válvulas TAVR, stents y ablación cardiaca; Neurociencia $10,300 millones (28%) — columna, neuroestimuladores, navegación; Médico-Quirúrgico $8,900 millones (24%) — grapadoras, energía, monitoreo; Diabetes $3,100 millones (9%) — bombas MiniMed, en separación.

Resultados. Fiscal 2026: ingresos $36,400 millones, +8.4% reportado / +5.8% orgánico — el mayor crecimiento en 10 años; utilidad ajustada por acción $5.53. Cuarto trimestre (3 de junio de 2026): $9,810 millones (+9.9% / +6.6% orgánico, ~1.5% arriba del consenso), utilidad ajustada $1.55 vs $1.54 esperado; la acción subió ~7%. Guía fiscal 2027: orgánico 6.75–7.25%, utilidad ajustada $5.90–6.00 (+6.7–8.5%). Reporta el primer trimestre fiscal 2027 el 1 de septiembre de 2026 (consenso ~$1.39, +9.5%).

Catalizadores. (1) Ablación por campo pulsado (PFA): su negocio de ablación cardiaca creció ~50% en fiscal 2026 con PulseSelect y Affera/Sphere-9; en junio anunció inversión para ampliar la capacidad de manufactura de Affera. (2) Robot Hugo: autorización FDA para urología el 3 de diciembre de 2025; primer caso comercial en EE.UU. el 17 de febrero de 2026 (Cleveland Clinic); más indicaciones en trámite. (3) Separación de Diabetes: MiniMed salió a bolsa el 6 de marzo de 2026 (Nasdaq: MMED; IPO a $20, hasta $644 millones; CEO Que Dallara); split-off completo esperado para fin de 2026. Diabetes creció 12.9% en fiscal 2026.

Retorno al accionista. Dividendo trimestral $0.72 ($2.88 anual, ~3.2%): 49º aumento anual consecutivo — a un año del estatus Dividend King; fiscal 2026 pagó ~$3,600 millones en dividendos ($4,200 millones devueltos en total) con flujo libre de ~$5,400 millones. Recompras: 10 millones de acciones en fiscal 2026 a promedio de $93.25; ~$1,200 millones restantes de la autorización de $5,000 millones.

Acción. $90.75 de apertura (31 de agosto de 2026); rango 52 semanas $73.31–$106.33; capitalización ~$115,800 millones; P/E 24.3x TTM / 14.1x forward. Consenso Buy (25 analistas), target promedio ~$98.84 (+9%; rango $78–121).

Riesgos. (1) Competencia PFA: Boston Scientific (Farapulse) lidera con >500,000 pacientes y ~80% del mercado de ablación de FA en EE.UU.; J&J y Abbott compiten. (2) Hugo vs Intuitive Surgical: autorizado solo para urología. (3) Aranceles: ~$250 millones de impacto neto estimado en fiscal 2027. (4) Apalancamiento de utilidad débil: fiscal 2026 con ventas +8.4% pero utilidad ajustada +0.7%; aumentos de dividendo simbólicos recientes (payout ~76%). (5) Ejecución del split-off de MiniMed (estructura y tiempos no finales) y pérdida de su unidad de mayor crecimiento. (6) Resultados del primer trimestre fiscal 2027 el 1 de septiembre de 2026.

More picks in Healthcare

See all Healthcare picks →

Researched: 8/31/2026Updated: 8/31/2026Next review: 2/28/2027

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.